FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
The key to fibrinolysis and thrombolysis
1709PDF: 531HTML: 264 -
Diagnosis and management of abnormal uterine bleeding in adolescence An expert Consensus Statement of SIGO (Italian Society of Gynecology and Obstetrics) and SISET (Italian Society for the Study of Hemostasis and Thrombosis)
2872PDF: 746 -
The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey
1371PDF: 221HTML: 137Appendix: 121 -
Inherited platelet function disorders: a comprehensive narrative review focusing on diagnostic and management aspects
94PDF: 49SUPPLEMENTARY MATERIAL: 20 -
Crosstalk between hemostasis inhibitors and cholesterol biomarkers in multiple sclerosis
2866PDF: 501Supplementary Files: 147 -
CO034 | VALIDATION OF A MICROFLUIDIC PLATFORM FOR HEMOSTASIS EVALUATION UNDER FLOW CONDITIONS: FROM PATHOGENETIC MECHANISMS TO THERAPEUTIC MONITORING F. Boggio1|2, L. Padovan1|2, S. La Marca1, G. Donadoni1, A. Lecchi1|2, A. Artoni1, S. Bozzi3, A. Redaelli3, F. Peyvandi1|2 | 1Centro Emofilia e Trombosi A. Bianchi Bonomi, IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico di Milano, Italy; 2Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Italy; 3Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Italy
61PDF: 19 -
Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers
942PDF: 123HTML: 130Supplementary: 79Appendix: 80 -
CO-85 | ACQUIRED HEMOPHILIA A IN LIVER CIRRHOSIS: BALANCING HEMOSTASIS BETWEEN HIGH HEMORRHAGIC AND THROMBOTIC RISKS N. Portesi, G. Martini | ASST Spedali Civili di Brescia, Italy
59PDF: 29 -
Availability of direct oral anticoagulants testing among Italian anticoagulation clinics: a rapid evolution of clinical practice On behalf of the Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies
882PDF: 103 -
CO-78 | REAL-WORLD MANAGEMENT OF ACQUIRED HEMOPHILIA A: FOCUS ON RECOMBINANT PORCINE FVIII AS FIRST-LINE HEMOSTATIC TREATMENT AND LONG-TERM OUTCOMES M. Leotta, A. Strangio, A. Ierardi, R.C. Santoro | Hemophilia, Hemostasis and Thrombosis Centre, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
55PDF: 20 -
CO003 | GENOMIC INCIDENTAL FINDINGS IN DISORDERS OF HEMOSTASIS M. D'Apolito, G D'Andrea, G.P. Palladino, C. Ceccarini, G. Cordisco, A. Leccese, I. Adipietro, P. Stanziale, M. Margaglione, R. Santacroce | Medical Genetics, Dept. of Clinical and Experimental Medicine, University of Foggia, Italy
147PDF: 22 -
PO130 | HEMORRHAGIC AND THROMBOTIC COMPLICATIONS DURING DOACS TREATMENT: THE IMPORTANCE OF A REGULAR AND PROLONGED FOLLOW-UP D. Barcellona1|2, A. Mameli2, S. Cornacchini2, P. Schirru2, L. Fenu2, V. Casu2, F. Marongiu1|2 | 1University of Cagliari, Italy; 2Haemostasis and Thrombosis Unit, Azienda Ospedaliero-Universitaria di Cagliari, Italy
60PDF: 15 -
PO47 | Hemophilia A and antithrombin deficiency: a case of natural hemostatic rebalancing L. Torrieri, S. Ligia, E. Baldacci, R. Mormile, S. Sorella, R. Ciciani, M. Biglietto, N. Zhdanovskaya, A. Delli Paoli, A. Tirnetta, M. Lorenzon, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy
641PDF: 19 -
PO075 | HEMOSTATIC AND CARDIOVASCULAR PROFILES IN HEMOPHILIA PATIENTS WITH AND WITHOUT ATHEROSCLEROSIS A. Napolitano, E. Zanon, L. Spiezia, G. Camporese, P. Scarinzi, F. Ahmad, G. Saggiorato, C. Bulato, F. Sartorello, S. Toffanin, A. Montagna, V. Azzaro, C. Simion, E. Campello, P. Simioni | Department of Medicine, University of Padova, Italy
38PDF: 19 -
PO34 | INVESTIGATORS’ DECISIONS ON ANTICOAGULATION AFTER EXTENDED API-CAT TREATMENT FOR CANCER VENOUS THROMBOEMBOLISM I. Mahé1|4, F. Happe2, M. Monreal5|7, H. Robert-Ebadi8, P. Debourdeau9, J. R. Fabreguettes10, S. Accassat11, P. Mismetti4|11|12, P. Girard13, S. Laporte4|12|14, C. Chapelle14 | 1Paris Cité University; 2Assistance Publique - Hôpitaux de Paris, Louis Mourier Hospital, Department of Internal Medicine; 3Inserm UMR-S970, Paris Cardiovascular Research Center, Team « Endotheliopathy and Hemostasis Disorders », Paris, France; 4F-CRIN INNOVTE Network, France; 5Department of Internal Medicine, Institut de Recerca Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 6Department of Medicine, Universitat Autonoma de Barcelona, Barcelona; 7Universidad Catolica San Antonio de Murcia, Murcia, Spain; 8Division of Angiology and Hemostasis, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland; 9Arles Hospital, Oncology unit, Arles, France; 10Assistance Publique - Hôpitaux de Paris, AGEPS, France; 11Service de Médecine Vasculaire et Therapeutique, CHU de Saint-Etienne, Saint-Etienne, France; 12Université Jean Monnet, Mines Saint-Étienne, INSERM Unité 1059, Santé Ingénierie Biologie Saint-Étienne SAINBIOSE, Saint-Étienne, France; 13Département de Pneumologie, Institut Mutualiste Montsouris, Paris; 14Service de Pharmacologie Clinique, CHU de Saint-Etienne, Saint-Etienne, France
444PDF: 95 -
CO30 | Joint prosthetic surgery in patients with hemophilia A: clinical-functional outcomes and quality of life E. Zanon1, A. Napolitano1, A. Berizzi2, P. Simioni1 | 1Haemophilia Center, First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua; 2Orthopedics and Traumatology Unit, University-Hospital of Padua Medical School, Padua, Italy
704PDF: 40 -
CO-51 | HEMOSTATIC AND CARDIOVASCULAR PROFILES IN HEMOPHILIA PATIENTS WITH AND WITHOUT ATHEROSCLEROSIS A. Napolitano, E. Zanon, L. Spiezia, G. Camporese, P. Scarinzi, F. Ahmad, G. Saggiorato, C. Bulato, S. Toffanin, S. Gavasso, F. Sartorello, C. Simion, E. Campello, P. Simioni | Hemophilia Center, University Hospital of Padua, Italy
55PDF: 18 -
Bleeding complications of oral anticoagulant therapy: from ISCOAT to the START Register A memory of Gualtiero Palareti
1739PDF: 244 -
CO-37 | STEW-EFA STUDY: MULTICENTER EVALUATION OF ONE-STAGE AND CHROMOGENIC ASSAYS FOR EFANESOCTOCOG ALFA MEASUREMENT ON STAGO AND WERFEN PLATFORMS A.C. Molinari1, M. Marchetti2, A. Catalano3, L. Contino4, R. De Cristofaro5, A.B. Federici6, T. Martini7, I. Quaglia8, R. Rossi9, R. Santoro10, A. Tripodi11, A. Valpreda12 | 1Regional Reference Centre for Hemorrhagic Diseases, Department of Hemato-Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy; 2Department of Immunohematology and Transfusion Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy; 3Società per la Promozione dell'educazione Medica (S.P.E.Me), Italy; 4Hemostasis and Thrombosis Unit, AOU SS Antonio e Biagio e C Arrigo, Alessandria, Italy; 5Dipartimento di Medicina e Chirurgia Traslazionale, Facoltà di Medicina e Chirurgia "Agostino Gemelli," Università Cattolica S. Cuore, Roma, Italy - Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario "A. Gemelli" Istituto di Ricerca e Cura a Carattere Scientifico, Roma, Italy; 6School of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy; 7Hemophilia Centre, Immune-Hematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza", Torino, Italy; 8Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy; 9Laboratory of Clinical Chemistry and Hematology, University Hospital of Parma, Italy; 10Hemophilia, Hemostasis, and Thrombosis Unit, Azienda Ospedaliero Universitaria Dulbecco, Catanzaro, Italy; 11IRCCS Ca' Granda Maggiore Hospital Foundation and Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy; 12Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Turin, Italy, reference laboratory of the Regional Center for Hemostasis and Thrombosis.
44PDF: 19 -
Welcome to the 12th International Conference on Thrombosis and Hemostasis Issues in Cancer! Oral Communications and Posters
924PDF: 579 -
PO048 | EFFICACY OF RITUXIMAB TREATMENT IN A CASE OF A RELAPSED AND REFRACTORY ACQUIRED VON WILLEBRAND DISEASE SECONDARY TO PRIMARY CUTANEOUS MARGINAL ZONE B-CELL LYMPHOMA L. Gurgoglione1, F. Saladino2, E. Morsia2, N. Viola3, S. Rupoli1, A. Poloni2 | 1Clinical Hematology, AOU delle Marche, Ancona, Italy; 2Università Politecnica delle Marche, Ancona, Italy; 3Clinical Immulogy, AOU delle Marche, Ancona, Italy
36PDF: 24 -
CO-86 | A RARE CASE OF ACQUIRED HEMOPHILIA A ASSOCIATED WITH MYELOPROLIFERATIVE NEOPLASM A. Ierardi, A. Strangio, M. Leotta, R.C. Santoro | Hemophilia, Hemostasis and Thrombosis Unit, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
58PDF: 22 -
CS07 | Endothelial dysfunction and impaired angiogenesis in Hermansky-Pudlak syndrome (HPS) type 1: studies with endothelial colony forming cells F. Tondi1, G. Purgatorio1, C. Sgromo2, E. Giglio1, E. Petito1, E. Falcinelli1, G. Guglielmini1, A. Follenzi2, P. Gresele1, L. Bury1*, C. Olgasi3* | *Shared senior authorship; 1Department of Medicine and Surgery, Section of Internal and Cardiovascular Medicine, University of Perugia; 2Department of Health Sciences, School of Medicine, University of Piemonte Orientale, Novara; 3Department of Translational Medicine, School of Medicine, University of Piemonte Orientale, Novara, Italy
305 -
PO079 | PERIOPERATIVE MANAGEMENT OF MILD-TO-MODERATE HEMOPHILIA: A COMPARATIVE STUDY OF EXTENDED HALF-LIFE VERSUS STANDARD HALF-LIFE CONCENTRATES ON CLINICAL OUTCOMES AND FACTOR CONSUMPTION M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, S. Bergonzi1|2|3, G. Murante1|2|3, A. Valpreda4, R. Pastorino1|3, F. Bocchi1|3, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Torino, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, Università di Torino, Torino, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Torino, Italy; 4Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Università di Torino, Torino, Italy
56PDF: 21 -
CO-23 | PERIOPERATIVE MANAGEMENT OF MILD-TO-MODERATE HEMOPHILIA: A COMPARATIVE STUDY OF EXTENDED HALF-LIFE VERSUS STANDARD HALF-LIFE CONCENTRATES ON CLINICAL OUTCOMES AND FACTOR CONSUMPTION M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, S. Bergonzi1|2|3, G. Murante1|2|3, A. Valpreda4, R. Pastorino1|3, F. Bocchi1|3, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Torino, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, University of Turin, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 4Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, University of Turin, Italy
63PDF: 19 -
CO062 | REDUCED-DOSE DOACs IN EXTENDED TREATMENT OF CANCER-ASSOCIATED THROMBOSIS (RED-CAT): INTERIM ANALYSIS FROM A MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY (COORDINATING CENTER DATA) S. Bergonzi1|2|3, A. Ghigo4, L. Carpisassi4, G. Murante1|2|3, M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, A. Valpreda3|5, R. Pastorino3|5, F. Bocchi3|5, A. Porreca6|7, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Turin, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, Università di Torino, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 4Division of Internal Medicine, AOU Città della Salute e della Scienza, Università di Torino, Italy; 5Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Università di Torino, Italy; 6Department of Human Sciences and Quality of Life Promotion, San Raffaele University, Roma, Italy; 7Clinical and Molecular Epidemiology, IRCCS San Raffaele, Roma, Italy
51PDF: 25 -
PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) J. Zwicker1, M. P. O’Brien2, M. Carrier3, J. Connors4, A. Falanga5, A. Manzano6, R. Mcbane7, Y.Y. Janjigian1, G. O’Kane8, M. Onisko2, J. Kaplan2, A.P. Kithcart2, D.E. Gutstein2, A. Khorana9, M. F. Walsh2 | 1Memorial Sloan Kettering Cancer Center, New York, USA; 2Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 3University of Ottawa, Ottawa, ON, Canada; 4Harvard Medical School, Boston, MA, USA; 5Hospital Papa Giovanni XXIII, Bergamo, Italy; 6Hospital Universitario 12 de Octubre, Madrid, Spain; 7Mayo Clinic, Rochester, MN, USA; 8St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; 9James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
531PDF: 126 -
CO32 | Major surgery in patients with severe hemophilia A without inhibitors receiving prophylaxis with fitusiran E. Zanon, C. Simion, A. Napolitano, L. Spiezia, P. Simioni | Haemophilia Center, First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
579PDF: 32 -
PO118 | VARIATION OF EGFR IN PATIENT IN DOACS THERAPY S. Vivolo, C. Gagliardi, A. Ciampa | U.O.S.D. Centro Emostasi Aorn S. G. Moscati Avellino, Italy
48PDF: 24 -
CO-65 | COVID-19-ASSOCIATED HYPERCOAGULABILITY IN TYPE 2B VON WILLEBRAND DISEASE: INSIGHTS FROM GLOBAL HEMOSTATIC ASSAYS I. Condonato, C. Simion, E. Zanon, P. Simioni | Hemophilia Center, University Hospital of Padua, Italy
62PDF: 24 -
PO033 | PLATELET COUNT AND PERIPROCEDURAL MAJOR BLEEDING IN CIRRHOTIC PATIENTS UNDERGOING INVASIVE PROCEDURES: INDIVIDUAL PATIENT DATA META-ANALYSIS E. Tarasconi1|2, E. Pontisso1, M. Manzoni1, S. Birocchi1, B. Clerici1, E.G. Giannini3, A. Iacobellis4, Shalimar5, P. Ponzo6, F. Giuliante7, A. Lauterio8, L. Massicotte9, N. Cocero10, V. Ronca11, G.M. Podda1|2 | 1S.C. Medicina Generale II, Ospedale San Paolo Polo Universitario, ASST Santi Paolo e Carlo, Università degli Studi di Milano, Italy; 2Dipartimento di Scienze della Salute (DISS), Università degli Studi di Milano, Italy; 3Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Italy; 4Department of Gastroenterology and Endoscopy, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; 5Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, India; 6Division of Gastroenterology and Hepatology, Città della Salute e della Scienza Hospital, University of Torino, Italy; 7Hepatobiliary Surgery Unit, Foundation and Teaching Hospital Sacred Heart IRCCS A. Gemelli, Catholic University of the Sacred Heart, Roma, Italy; 8General Surgery and Abdominal Organ Transplantation, ASST Grande Ospedale Metropolitano Milano Niguarda School of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy; 9Department of Anesthesiology, Centre Hôspitalier de l’Université de Montréal- Hôpital Saint-Luc, Montreal, Canada; 10Senior Consultant, Oral Surgery Section of the Dental School of the University of Torino at the Azienda Ospedaliera Città della Salute e della Scienza of Torino, Italy; 11IRCCS Humanitas Research Hospital, Department of Gastroenterology, Division of Internal Medicine and Hepatology, Milano, Italy. E. Tarasconi and E. Pontisso contributed as co-first authors
40PDF: 20 -
Whole exome sequencing in a family with thromboangiitis obliterans
1132PDF: 130SUPPLEMENTARY FILES: 101 -
CO-21 | FUSION 2: VALIDATION AND CLINICAL PERFORMANCE OF AN INTEGRATED ULTRASOUND–FUNCTIONAL ASSESSMENT SYSTEM IN HEMOPHILIA M.E. Susi1, E.A. Boccalandro2, A. Giuffrida3, I. Ricca4, P. Imazio5, E. Bonetti6, I. Nichele7 B. Pollio8, E. Zanon9, E. Baldacci10, C. Santoro10, G. Delios4, S. Ligia10, M. Biglietto10, I. Calcaterra11, M. Napolitano12, M. Bodini2, C. Simion9, B. Borsellino8, G. Pasta13, M.N.D. Di Minno11, C. Martinoli14|15 | 1DIMES, Department of Experimental Medicine, University of Genoa, Italy; 2Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milano, Italy; 3Hemophilia Center, Borgo Roma Hospital, Integrated University Hospital of Verona, Italy; 4Immunology and Transfusion Medicine Service, Hemophilia Center, Ivrea Hospital, Local Health Authority TO4, Ivrea, Italy; 5Rehabilitation and Functional Recovery Service, Pediatric Orthopedics Unit, Regina Margherita Children’s Hospital, City of Health and Science University Hospital of Turin, Italy; 6Pediatric Oncohematology Unit, Borgo Trento Hospital, Integrated University Hospital of Verona, Italy; 7Haemophilia and Thrombosis Center, Haematology Department, San Bortolo Hospital, Vicenza, Italy; 8Transfusion Medicine and Immunohematology Service, Regina Margherita Children’s Hospital, City of Health and Science University Hospital of Turin, Italy; 9Coagulation Disorders and Hemophilia Center, University Hospital of Padova, Italy; 10Unit of Special Diagnosis and Therapy of Hemostasis and Thrombosis, Hematology Department, Policlinico Umberto I, Sapienza University of Rome, Italy; 11Department of Clinical Medicine and Surgery, Regional Reference Centre for Coagulation Disorders, Federico II University, Napoli, Italy; 12Dipartimento PROMISE, Università degli Studi di Palermo and UOC Ematologia e Malattie Rare, PO “Cervello”, Palermo, Italy; 13Orthopedics and Traumatology Clinic, IRCCS Policlinico San Matteo Foundation, Pavia, Italy; 14DISSAL, Department of Health Sciences, University of Genoa, Italy; 15UOC Emergency and Musculoskeletal Radiology, IRCCS AOM San Martino Hospital, Genova, Italy
59PDF: 20 -
CO061 | IMMUNOFLUORESCENCE MICROSCOPY REVEALS PLATELET- AND RED BLOOD CELL ALTERATIONS AS MORPHOLOGICAL BIOMARKERS IN MYELOPROLIFERATIVE NEOPLASMS C. Zaninetti1, L. Kaderali2, L. Vater1, S. Semenowitsch1, L. Porges1, T.M. Schnöder3|4, C.C. Crodel5, J. Fuhrmann1, J. Wesche1, C. Freyer1, T. Thiele1, F.H. Heidel3|6, A. Greinacher1 | 1Institut für Transfusionsmedizin Universitätsmedizin Greifswald, Greifswald, Germany; 2Institut für Bioinformatik, Universitätsmedizin Greifswald, Greifswald, Germany; 3Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany; 4Innere Medizin C, Universitätsmedizin Greifswald, Greifswald, Germany; 5Innere Medizin II, Abt. Hämatologie und Onkologie, Universitätsklinikum Jena, Jena, Germany; 6Leibniz Institute on Aging, Fritz-Lipmann Institute, Jena, Germany
48PDF: 20 -
PO104 | BLEEDING AND THROMBOTIC OUTCOMES DURING EXTENDED DIRECT ORAL ANTICOAGULANT THERAPY: AN EIGHT YEAR RETROSPECTIVE ANALYSIS G. Sottilotta1, G. Praticò1, S. Cuzzocrea1, D. Megalizzi1, F. Luise2 | 1UOSD Microcitemie - Emostasi e Trombosi. Grande Ospedale Metropolitano di Reggio Calabria, Italy; 2Laboratorio Analisi. Grande Ospedale Metropolitano di Reggio Calabria, Italy
60PDF: 24 -
CO-57 | NXT007 PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS: COMBINED ANALYSIS OF TWO PHASE I/II MULTIPLE-ASCENDING-DOSE STUDIES M.E. Mancuso1|2, M. Shima3, J.M. Staber4, Y.C. Chen5, F.J. López-Jaime6, M.C. Shen7, G. Ventriglia8, M. Takeyama9, C. Schmitt8, Y.S. Park10, A. Kiialainen8, N. Mizuno11, M. Niggli8, T. Miyake11, D. Matino12, T. Saito11, V. Jiménez-Yuste13, R. Kobayashi11, D. Hart14, K. Nogami15 | 1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy; 2Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 3Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Nara, Japan; 4Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, USA; 5Hemophilia Care and Research Center, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan; 6Servicio de Hematología, Hospital Universitario Regional de Málaga / Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain; 7Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan; 8F. Hoffmann-La Roche Ltd, Basel, Switzerland; 9Division of Hemophilia, National Hospital Organization, Osaka National Hospital, Osaka, Japan; 10Department of Pediatrics, Kyung Hee University Hospital at Gangdong, Seoul, South Korea; 11Chugai Pharmaceutical Co., Ltd, Tokyo, Japan; 12McMaster University, Hamilton, Ontario, Canada; 13La Paz University Hospital-IdiPAZ, Autónoma University, Madrid, Spain; 14Roche Products Ltd, Welwyn Garden City, UK; 15Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
71PDF: 21 -
PO012 | RECURRENT CENTRAL RETINAL VEIN THROMBOSIS IN A PATIENT WITH MILD HEMOPHILIA A AND HETEROZYGOSITY FOR THE PROTHROMBIN G20210A VARIANT I. Zatta1, E. Pacquola1, L. Di Daniel2, C. Simion3, E. Zanon3, P. Simioni3, S. Villalta2, L. Abbruzzese1 | 1Medicina Trasfusionale Osp. Ca’ Foncello, Treviso, Italy; 2Medicina Generale Osp. S. Giacomo, Castelfranco V.to, Italy; 3Clinica Medica 1° Azienda-Ospedale Università, Padova, Italy
68PDF: 27 -
PO44 | Emicizumab in acquired haemophilia A M. Leotta, A. Strangio, A. Ierardi, S. Prejanò, R C. Santoro | Hemostasis and Thrombosis Unit, Department Hemato-Oncology, Azienda Ospedaliero-Universitaria Renato; Dulbecco, Catanzaro, Italy
636PDF: 27 -
CO-84 | PARAPROTEIN-DRIVEN ACQUIRED VON WILLEBRAND SYNDROME IN A PATIENT WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND UROTHELIAL CARCINOMA A. Ierardi, A. Strangio, M. Leotta, R.C. Santoro | Hemostasis Unit, AOU Dulbecco, Catanzaro, Italy
49PDF: 21 -
PO069 | PERIOPERATIVE CHALLENGES IN ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA DURING CAPLACIZUMAB TREATMENT J. Agnelli Giacchello1, P. Sciancalepore1, N.F. Trincheri2, L. Contino1, M. Ladetto3, R.M. Santi1 | 1SSD Emostasi e trombosi e malattie rare; 2SC Laboratorio Analisi; 3SCDU Ematologia, AOU SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
48PDF: 22 -
CO-10 | APPLICATIONS OF ARTIFICIAL INTELLIGENCE IN HEMOPHILIA MANAGEMENT: INNOVATIONS AND FUTURE PERSPECTIVES A. Ierardi, M. Leotta, A. Strangio, S. Prejanò, R.C. Santoro | UO Hemophilia, Hemostasis and Thrombosis. Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
118PDF: 20 -
PO22 | LONG-TERM ANTICOAGULANT THERAPY AND REDUCTION OF OVARIAN CANCER RECURRENCE: CLINICAL EVIDENCE OF A POTENTIAL ANTITUMOUR EFFECT J. Khizroeva1, V. Bitsadze1, A. Vorobev1, A. Solopova1, M. Tretyakova1, N. Gashimova1, K. Grigoreva1, A. Khisamieva1, J. Gris1|2, I. Elalamy1|3|4, G. Gerotziafas1|3|4, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University, Moscow, Russia; 2Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 3Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 4Hospital Tenon, Paris, France
433PDF: 92 -
CO22 | Assessment of coagulation profiles in septic patients using viscoelastic coagulation monitoring and rotational thromboelastometry in an internal medicine setting G. Gottardi, C. Simion, D. Regazzo, C. Samà, G.P. Arcidiacono, L. Gianesello, E. Campello, P. Simioni | Department of Medicine – DIMED, University of Padua, Italy
574PDF: 32 -
PO102 | EFFICACY AND SAFETY OF VISCOELASTIC TESTING–GUIDED TRANSFUSION IN CIRRHOSIS UNDERGOING INVASIVE PROCEDURES: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS A. Boccatonda1, E. Campello2, A. Napolitano2, C. Simion2, C. Serra1, P. Simioni2 | 1Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Via Massarenti N 9, 40138, Bologna, Italy; 2First Chiar of Internal Medicine and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University Hospital of Padova, 35128, Padova, Italy
42PDF: 20 -
CO-56 | EVALUATING AN AI MODEL’S HEMATOLOGY CONSULTATION PERFORMANCE FOR HOSPITALIZED PATIENTS WITH BLEEDING DISORDERS G. Sottilotta1, F. Misiti2, G. Praticò1, D. Megalizzi1, F. Luise3 | 1UOSD Microcitemie - Emostasi e Trombosi. Grande Ospedale Metropolitano di Reggio Calabria, Italy; 2Associazione Emofilici di Reggio Calabria, Italy; 3Laboratorio Analisi. Grande Ospedale Metropolitano di Reggio Calabria, Italy
62PDF: 20 -
CO099 | OPTIMIZING CUT-OFFS FOR LUPUS ANTICOAGULANT TESTING: EVIDENCE FROM A MULTICENTER REGIONAL STUDY S. Nannini1, G. Andreani2, C. Bellini3, M. Bombara4, S. Brizzi1, P. Calzoni5, M. Casini6, F. Cesari7, D. Fineschi8, A.M.G. Gelli9, L. Iordache10, M. Lorubbio11, M. Martelloni9, A. Rogolino7, V. Scaccia3, M. Spagnuolo4, A. Terrosi3, F. Veneziani12, R. Marcucci7, A.M. Gori7 | 1SOS Patologia Clinica San Jacopo, Pistoia e SS Cosma e Damiano, Pescia, Azienda USL Toscana Centro, Italy; 2S.S.D Analisi Chimico-Cliniche Apuane e Microbiologia molecolare, Osp. delle Apuane, Azienda U.S.L Toscana Nord-Ovest, Italy; 3Lab. Analisi Chimico-Cliniche, Dip. di Medicina Diagnostica, Trasfusionale e Dei Servizi, Osp. Misericordia Grosseto AUSL TSE, Italy; 4Azienda USL Toscana Nordovest - Dipartimento Diagnostiche di Laboratorio, U.O.C. Laboratorio Analisi Chimico Cliniche, Ambito Territoriale Livorno, Italy; 5UOS Coagulazione, UOC Laboratorio di Patologia Clinica, AOU Senese, Italy; 6U.O. Analisi Chimico-Cliniche Azienda Ospedaliero Universitaria Pisana, Italy; 7Azienda Ospedaliero Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze, Italy; 8UOC Laboratorio di Patologia Clinica, AOU Senese, Italy; 9SOS Patologia Clinica PO San Giuseppe, Empoli, Italy; 10Laboratorio Di Analisi Chimico-Cliniche E Microbiologiche, Ospedale Santo Stefano, Prato, Italy; 11UOSD Medicina di Laboratorio Valdarno, Azienda USL Toscana Sud Est, Arezzo, Italy; 12Laboratorio Patologia Clinica, Ospedale San Giovanni di Dio, Firenze, Italy
48PDF: 26 -
PO42 | Acquired Von Willebrad syndrome in patients with myeloproliferative syndrome: literature review and single-center experience A. Strangio, M. Leotta, A. Ierardi, R C. Santoro | UO Emofilia, Emostasi e Trombosi, AOU R Dulbecco, Catanzaro, Italy
565PDF: 31 -
CO-82 | ACQUIRED SEVERE FACTOR XIII DEFICIENCY AS THE INITIAL PRESENTATION OF PAEDIATRIC ACUTE PROMYELOCYTIC LEUKAEMIA C. Vernarecci, G. Gazzelli, L. Banov, F. Marotta, F. Giacopelli, B. Tappino, B. Antonioli, A.C. Molinari | IRCCS Istituto Giannina Gaslini, Genova, Italy
79PDF: 15 -
PO068 | ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH MULTIPLE SCLEROSIS AND MS-LIKE DISEASES: MS OR APS? M. Gagliardi, L. Capone, A. Ciampa | Centro Emostasi, AORN Moscati, Avellino, Italy
37PDF: 26 -
BEST-07 | ULTRASOUND EVALUATION AND JOINT SCORING IN MILD HEMOPHILIA A: A SINGLE-CENTER CASE SERIES FOR THE IDENTIFICATION OF SUBCLINICAL ARTHROPATHY M. Leotta, A. Strangio, R.C. Santoro | Hemophilia Hemostasis and Thrombosis Unit, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
152PDF: 19 -
PO79 | Trying to hit the hit in the shadow of renal failure: a complex case managed with danaparoid S. Chessa1,2, M. Anedda2, M.V. Cherchi2, M. Vacca1,2, M. Caboni2, J. Pilia2, A.M. Bussu2, M. Mantega2, G. Costanzo1, D. Firinu1, S. Del Giacco1, A. Mameli3, D. Barcellona3 | 1Department of Medical Science and Public Health, University of Cagliari; 2Internal Medicine, ASL Sulcis, PO Sirai, Carbonia; 3Department of Medical Sciences and Public Health, Hemostasis and Thrombosis Unit, University of Cagliari and AOU of Cagliari, Italy
673PDF: 16 -
CO011 | GENERATION OF A TARGETING NON-BLOCKING TISSUE FACTOR ANTIBODY FOR SAFE AND EFFICACIOUS CANCER TREATMENTS A. Metelli1, P. Nisticò1, J. Wrangle2 | 1IRCCS Regina Elena National Cancer Institute, Roma, Italy; 2Medical University of South Carolina, Charleston, USA
144PDF: 16 -
PO20 | DYSFUNCTION OF THE ADAMTS-13/VON WILLEBRAND FACTOR AXIS, MEDIATED BY NETOSIS, AS A DRIVER OF PROTHROMBOTIC STATE AND UNFAVORABLE PROGNOSIS IN ONCOGYNECOLOGICAL PATIENTS V. Bitsadze1, E. Beloborodova2, J. Khizroeva1, A. Solopova1, M. Tretyakova1, N. Gashimova1, K. Grigoreva1, A. Tatarintseva1, J. Christophe Gris1|3, I. Elalamy1|4|5, G. Gerotziafas1|4|5, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 2Clinic MEDSI Network of Medical Centers in Moscow, Russia; 3Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 4Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 5Hospital Tenon, Paris, France
500PDF: 97 -
CO10 | Multidimensional risk assessment of venous thromboembolism: an observational study comparing the Padua prediction score, Barthel index, and quality of life in hospitalized patients A. Mameli, S. Cornacchini, P. Schirru, F. Marongiu, D. Barcellona | Hemostasis and Thrombosis Unit, University of Cagliari, Italy
700PDF: 34 -
PO101 | COMPREHENSIVE EVALUATION OF COAGULATION PROFILES IN REFRACTORY MODERATE-TO-SEVERE ULCERATIVE COLITIS L. Spiezia1, G. Di Lecce2, B. Barberio2, M. Zanconato2, E. Bicego1, C. Samà1, B. Serena1, M. De Bona3, A. Buda3, F. Zingone2, E.V. Savarino2, P. Simioni1 | 1First Chair of Internal Medicine, Department of Medicine (DIMED), Padova University Hospital, Padova, Italy; 2Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, Padova, Italy; 3Gastroenterology Unit, Department of Oncological Gastrointestinal Surgery, S. Maria del Prato Hospital, Feltre, Italy
47PDF: 25 -
CO-55 | DEVELOPMENT OF ENGINEERED LONG-ACTING BYPASSING FX VIA ALBUMIN FUSION FOR HEMOPHILIA WITH INHIBITORS A. Martucci1, R. Tarantino1, K.H. Aaen2, M. Pinotti1, J.T. Andersen2, A. Branchini1 | 1Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy; 2Institute of Clinical Medicine, Department of Pharmacology, University of Oslo, Norway
70PDF: 20
